PREDICTORS OF CLINICALLY SIGNIFICANT PROSTATE CANCER WITH PIRADS CATEGORY 3 MPMRI LESIONS

被引：0
|
作者：
Zorawar, Singh [1 ]
Karen, Huang [1 ]
Derek, Tran [1 ]
Manish, Vira [1 ]
Simon, Hall [1 ]
机构：
[1] Northwell Hlth, New Hyde Pk, NY USA
来源：
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2025年 / 43卷 / 03期
关键词：
D O I：
10.1016/j.urolonc.2024.12.221
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
219
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Predicting clinically significant prostate cancer following suspicious mpMRI: analyses from a high-volume center
    Jahnen, Matthias
    Hausler, Tanja
    Meissner, Valentin H.
    Ankerst, Donna P.
    Kattan, Michael W.
    Sauter, Andreas
    Gschwend, Juergen E.
    Herkommer, Kathleen
    WORLD JOURNAL OF UROLOGY, 2024, 42 (01)
  • [42] Assessment of prostate imaging reporting and data system version 2.1 false-positive category 4 and 5 lesions in clinically significant prostate cancer
    Xiangyu Wang
    Weizong Liu
    Yi Lei
    Guangyao Wu
    Fan Lin
    Abdominal Radiology, 2021, 46 : 3410 - 3417
  • [43] PREDICTIVE VALUE OF PIRADS V2 FOR ANY AND CLINICALLY SIGNIFICANT PROSTATE CANCER ON PROSTATE BIOPSY IN A HIGH RISK ETHNIC COHORT
    Lin, Wilson
    Fram, Ethan
    Chernyak, Victoria
    Watts, Kara
    JOURNAL OF UROLOGY, 2018, 199 (04): : E183 - E184
  • [44] A multicenter study of artificial intelligence-aided software for detecting visible clinically significant prostate cancer on mpMRI
    Sun, Zhaonan
    Wang, Kexin
    Kong, Zixuan
    Xing, Zhangli
    Chen, Yuntian
    Luo, Ning
    Yu, Yang
    Song, Bin
    Wu, Pengsheng
    Wang, Xiangpeng
    Zhang, Xiaodong
    Wang, Xiaoying
    INSIGHTS INTO IMAGING, 2023, 14 (01)
  • [45] The Use of Multiparametric Magnetic Resonance Imaging (mpMRI) in the Detection, Evaluation, and Surveillance of Clinically Significant Prostate Cancer (csPCa)
    Parth Patel
    Shu Wang
    Mohummad Minhaj Siddiqui
    Current Urology Reports, 2019, 20
  • [46] PSA DENSITY (PSAD) ALONE OR WITH MULTIPARAMETRIC MRI (MPMRI) IS ROBUST AT PREDICTING CLINICALLY SIGNIFICANT PROSTATE CANCER (CSPCA)
    Pandya, Shashank S.
    Andreas, Darian
    Nethala, Daniel
    Lee, Jeffrey
    Hall, Simon J.
    JOURNAL OF UROLOGY, 2021, 206 : E506 - E506
  • [47] Variability of mpMRI diagnostic performance according to the upfront individual patient risk of having clinically significant prostate cancer
    Pellegrino, Francesco
    Stabile, Armando
    Sorce, Gabriele
    Mazzone, Elio
    Cannoletta, Donato
    Cirulli, Giuseppe Ottone
    Quarta, Leonardo
    Leni, Riccardo
    Robesti, Daniele
    Brembilla, Giorgio
    Gandaglia, Giorgio
    De Cobelli, Francesco
    Montorsi, Francesco
    Briganti, Alberto
    PROSTATE, 2024, 84 (05): : 473 - 478
  • [48] The learning curve of mpMRI targeted biopsy for the detection of clinically significant prostate cancer is related to the characteristics of the index lesion
    Stabile, A.
    Mazzone, E.
    Barletta, F.
    Bravi, C. A.
    Rosiello, G.
    Cucchiara, V.
    Sorce, G.
    Pellegrino, F.
    Zaffuto, E.
    Brembilla, G.
    Esposito, A.
    Gandaglia, G.
    Fossati, N.
    Gallina, A.
    Deho, F.
    De Cobelli, F.
    Montorsi, F.
    Briganti, A.
    EUROPEAN UROLOGY, 2021, 79 : S1324 - S1325
  • [49] The Use of Multiparametric Magnetic Resonance Imaging (mpMRI) in the Detection, Evaluation, and Surveillance of Clinically Significant Prostate Cancer (csPCa)
    Patel, Parth
    Wang, Shu
    Siddiqui, Mohummad Minhaj
    CURRENT UROLOGY REPORTS, 2019, 20 (10)
  • [50] Assessment of prostate imaging reporting and data system version 2.1 false-positive category 4 and 5 lesions in clinically significant prostate cancer
    Wang, Xiangyu
    Liu, Weizong
    Lei, Yi
    Wu, Guangyao
    Lin, Fan
    ABDOMINAL RADIOLOGY, 2021, 46 (07) : 3410 - 3417
12345